Cell reports. Medicine

Targeting GLP-1 and GIP receptors with selective drugs improves blood sugar control and weight loss, with combined targeting working best

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Biased activation of GLP-1R or GIPR individually leads to improved glycemic control and weight loss.

  • Biased signaling of GLP-1R or GIPR is associated with better regulation of blood sugar levels.
  • Greater suppression of food intake is observed with biased agonism of either receptor.
  • Weight loss is linked to the individual biased activation of GLP-1R and GIPR.
  • Using a combined approach with a dual agonist, CT-859, may enhance therapeutic efficacy compared to individual receptor activation.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Funding

Competing interests

Declaration of interests All authors are current or past employees of Carmot Therapeutics.
PubMed

Related papers

Nov '24
Loss of a specific signaling in inhibitory brain cells increases weight loss caused by GLP-1 receptor drugs
top 5% journal
cited by 19 papers
journal article
Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 11 papers
research support, non-u.s. gov't
Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 206 papers
research support, non-u.s. gov't
May '24
Less movement of incretin receptors after activation improves blood sugar control and reverses obesity in diet-induced obese mice
cited by 2 papers
journal article
May '20
Drug effects of single, double, and triple peptide activators on GIP and GLP-1 hormone receptors
top 10% journal
cited by 51 papers
research support, non-u.s. gov't
Jun '20
Fast identification of a new drug that activates two hormone receptors to improve blood sugar control and reduce weight in rodents
cited by 6 papers
journal article
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article
Apr '25
Activating or blocking GIPR reduces body weight and food intake through different ways in male mice
top 1% journal
cited by 26 papers
journal article
Sep '25
Designing triple hormone receptor activators with different strengths to achieve similar blood sugar and weight loss effects
top 10% journal
cited by 7 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief